| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Adolor Corporation |
| 371 Phoenixville Pike, Malvern, PA 19355 * (610) 889-5779 |
| Business Description | The company discovers, develops and plans to commercialize novel and proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by current narcotic pain treatments. |
|
Filing Information Not yet | |||
| To Trade As | ADOR (NASNTL) | Industry | Service (SIC 7841) |
| Type of Stock Offered | Common Shares | Filing Date | 2/7/00 |
| Domestic Shares Filed | 6,000,000 | Filing Range | $15.00 - $17.00 |
| Foreign Shares Filed | 0 | Offering Amount | $96,000,000 |
| Company Shares | 6,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 26,849,406 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| Pacific Growth Equities | Co-manager | (415) 274-6800 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.000 | 0.150 | 0.011 | - | - |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | - | - | -4.799 | -8.816 | -10.131 | - | - |
| E.P.S | - | - | -4.740 | -7.990 | -8.730 | - | - |
| Revenue Growth (%) | - | - | - | -92.689 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -8.78 | - | - | ||||
| Cash Flow - Inv. | -0.17 | - | - | ||||
| Cash Flow - Fin. | 2.44 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 6.26 | Current Assets | 5.45 | Current Ratio | 2.29 |
| Total Liab. | 35.85 | Current Liab. | 2.39 | Debt Ratio | 572.81% |
| Total Equity | -29.59 | Working Cap. | 3.07 | Debt to Equity Ratio | - |
| Cash | 3.47 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for the continued development of existing product candidates, research and development of additional product candidates, manufacturing, commercialization and marketing expenditures, expansion of our facilities, working capital and potential acquisitions of products, technologies or businesses. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Dechert Price & Rhoads |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Registrar/Transfer Agent | StockTrans, Inc. |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Alta California Management Partners, L.P. | 14.82 | |
| WPG Venture Partners III, L.P. | 14.59 | |
| Falcon Technology Partners, L.P. | 12.22 | |
| Technology Leaders Management, Inc. | 10.30 | |
| ARCH Venture Fund III, L.P. | 9.69 | |
| S.R. One, Limited | 9.13 | |
| One Liberty Partners III, L.P. | 5.72 | |
| ARCH Venture Fund II, L.P | 5.01 | |
| Note: represents ownership of 5% or more prior to the offering. | ||